Skip to main content

Measurement of anti SARS-CoV-2 RBD IgG in saliva: validation of a highly sensitive assay and effects of the sampling collection method and correction by protein.

Martínez-Subiela S, Franco-Martínez L, Rubio CP, Muñoz-Prieto A, Torres-Cantero A, Tecles F, Sánchez-Resalt C, Cerón JJ, Tvarijonaviciute A

Publication: Clin Chem Lab Med (2022)PMID: 35848513View on PubMed

Purpose

This paper compared levels of antibodies against the SARS-CoV-2 (the virus that causes the novel 2019 coronavirus disease (COVID, COVID-19, COVID19)) receptor binding domain (RBD) among serum and saliva specimens collected by passive drooling or using a Salivette collection device 24-48 h, 3 weeks, and 4 months post-vaccination.

Conclusion

Immunoglobin G (IgG) anti-RBD levels were strongly correlated between serum and saliva collected by either passive flow or using a Salivette collection device and between the two saliva samples collected by different methods. Levels of IgG anti-RBD were significantly lower in saliva collected using the Salivette device than by passive flow. IgG anti-RBD levels in both types saliva specimens and serum were higher 3 weeks post-vaccination than 24-48 h post-vaccination and 4 months post-vaccination. Saliva (both specimens), but not serum, also had significantly higher antibody levels 4 months post-vaccination than 24-48 h post-vaccination. The percentage of patients with IgG anti-RBD values above the threshold (3 standard deviations above pre-pandemic levels) was generally highest for serum, followed by passive flow saliva.  The authors report no effect of storing saliva or serum for 6 months at -80°C on IgG anti-RBD titers.

Studies (1)

Purpose

This study compared levels of IgG against SARS-CoV-2 RBD among serum and saliva specimens collected by passive drooling and using the Salivette collection device 24-48 h, 3 weeks and 4 months post-vaccination.  Paired saliva and serum were obtained from 35 patients (24 females and 11 males) 48-72 h, 3 weeks and 4 months after the second dose of a SARS-Cov-2 Vaccine (23 patients vaccinated with BNT162b2/Comirnaty, 12 with ChAdOx1-S/Vaxzevria). Saliva specimens were collected by two methods: passive drool for 2 min into a conical tube and using the cotton from a Salivette device for 1 min. Passive drool saliva was centrifuged at 4000 g for 10 min and Salivette saliva was centrifuged at 4500 g for 10 min. Immediately following saliva collection, blood was collected (tube unspecified) and transferred to a tube containing clot activators. Serum was obtained by centrifugation at 3000 rpm for 5 min. Saliva and serum were incubated with 0.5% NP-40 for 30 min to inactivate the virus and stored at -80°C. Protein content was quantified spectrophotometrically. IgG to the SARS-CoV-2 RBD was quantified using a two-step sandwich immunoassay.

Summary of Findings

Uncorrected IgG anti-RBD levels were strongly correlated between serum and saliva collected by either the passive flow (r=0.90, P<0.001) or Salivette device method (r=0.86, P<0.001), but the correlation between passive flow saliva and serum was lower after correction for protein levels (r=0.70, P<0.0001).  Levels of IgG anti-RBD were significantly lower in saliva collected using the Salivette device than specimens by passive flow (4.55 AU/mL versus 8.7 AU/mL, P<0.0001), but were strongly correlated between the two collection methods (r=0.86, P<0.0001).  The percentage of patients with IgG anti-RBD values above the threshold (3 standard deviations above pre-pandemic levels) was generally highest for serum followed by passive flow saliva; however, at 4 months post-vaccination a slightly higher percentage of passive flow saliva specimens than serum had levels above the cut off (62% versus 60%). IgG anti-RBD levels in both saliva specimens and serum were higher 3 weeks post-vaccination than 24-48 h post-vaccination (P<0.0001, all) and 4 months post-vaccination (P<0.0001, all).  Saliva (both specimen collection methods), but not serum, had significantly higher antibody levels 4 months post-vaccination than 24-48 h post-vaccination (P<0.5).  Importantly, higher IgG anti RBD levels were still observed in the saliva specimens collected by both methods 3 weeks post-vaccination than 24-48 h and 4 months post-vaccination after correction for protein content (P<0.0001).  The intra- and inter-assay CV for the IgG anti-RBD assay were 6-7% and 12-19%, respectively, for serum and 6-13% and 13-15%, respectively for saliva.  The authors report no effect of storing saliva or serum for 6 months at -80°C on IgG anti-RBD titers.

  • Biospecimens

    FluidSaliva
    FluidSerum
  • Preservation Types

    Frozen
  • Diagnoses

    Normal
  • Platforms

    GlycoproteinImmunoassay
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionBiospecimen location
    Saliva
    Serum
    Biospecimen AcquisitionMethod of fluid acquisition
    Non-stimulated saliva
    Stimulated saliva (chewing prior to collection)
    Biospecimen AcquisitionTime of biospecimen collection
    24-48 h post-vaccination
    3 weeks post-vaccination
    4 months post-vaccination